Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

Samsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Regeneron shows progress in gene therapy for congenital deafness. This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by ...

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to ...

Regeneron Pharmaceuticals is taking another shot at US Food and Drug Administration (FDA) accelerated approval for odronextamab in relapsed/refractory follicular lymphoma (r/r FL), with the agency ...

The Goldman Sachs equity team says it continues to recommend investors owning healthcare stocks. Healthcare "offers a ...

The deal with Regeneron comes months after CytomX Therapeutics laid off 40% of its workers. Image sourced from: Cancer Research UK / Shutterstock Nicole Raleigh ...

Ten children who received DB-OTO for profound genetic hearing loss due to variants of the otoferlin gene showed notable ...